Board of directors

  • Stephen Tullman

    Chairman

    Stephen Tullman has served as chairman of Aclaris’ board of directors since its inception in 2012. Mr. Tullman co-founded and currently serves as the managing member of NeXeption, LLC. He serves as the chairman of Onspira Therapeutics, Inc., a company he co-founded in 2017 to focus on addressing rare pulmonary diseases. He also serves as chairman of Velicept Therapeutics, Inc., a urology-focused company he co-founded in 2015. Mr. Tullman currently serves as the chairman of the board of directors of Ralexar Therapeutics Inc. and as a board member of several other privately held companies. He is the Chairman of Life Science Pennsylvania (LSPA), the statewide trade association for the Commonwealth’s life sciences community.

    Mr. Tullman served as chairman, president and CEO of Ceptaris Therapeutics Inc. from 2011 until its acquisition by Actelion US Holdings Company, a subsidiary of Actelion Pharmaceuticals Ltd, in 2013. Mr. Tullman served as chairman of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan in 2011. In 2005, Mr. Tullman co-founded Ception Therapeutics Inc. and served as its president and CEO until its acquisition by Cephalon Inc. in 2010. In 2003, Mr. Tullman co-founded Trigenesis Therapeutics, Inc. (acquired by Dr. Reddy's Laboratories Ltd.), where he served as its chief business officer. Mr. Tullman began his career at SmithKline Beecham, now GlaxoSmithKline (GSK), where he held positions of increasing responsibility in finance, sales, marketing, and research and development. Mr. Tullman received a Bachelor of Science in accounting from Rutgers University.

  • William Humphries

    Director

    William D. Humphries has served as a member of our board of directors since September 2016. Mr. Humphries is president and company group chairman of Ortho Dermatologics, a division of Bausch Health Companies Inc.  Previously, he was CEO of Merz North America where he oversaw strategic direction and collaboration among three North American companies: Merz Pharmaceuticals LLC, Merz Aesthetics Inc., and Merz Pharma Canada Ltd. Before joining Merz, he served as president of Stiefel where he spearheaded two significant acquisitions and led the global integration of Stiefel into GlaxoSmithKline. Previously, Mr. Humphries held multiple senior executive roles within Allergan Inc. He holds a Bachelor of Arts from Bucknell University and a Master of Business Administration from Pepperdine University.

  • Anand Mehra, M.D.

    Director

    Dr. Mehra has served as a member of Aclaris’ board of directors since September 2014. Dr. Mehra joined Sofinnova Ventures, a venture capital firm, in 2007 and currently serves as a general partner. Prior to joining Sofinnova Ventures, Dr. Mehra worked in J.P. Morgan's private equity and venture capital group, and before that, Dr. Mehra was a consultant in McKinsey & Company's pharmaceutical practice. Dr. Mehra currently serves on the boards of directors of Spark Therapeutics Inc., First Aid Beverages Inc., and Merus N.V. Dr. Mehra received his Bachelor of Arts in political philosophy from the University of Virginia and a Doctor of Medicine from Columbia University's College of Physicians and Surgeons.

  • Christopher Molineaux

    Director

    Christopher Molineaux has served as a member of our board of directors since January 2014. Mr. Molineaux is president and CEO of Life Sciences Pennsylvania, the life sciences industry advocacy organization for the Commonwealth of Pennsylvania. Before joining Life Sciences Pennsylvania in 2009, Mr. Molineaux served as worldwide vice president of pharmaceutical communication and public affairs for Johnson & Johnson. Mr. Molineaux previously served as vice president for public affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA) and held positions at the Federal Department of Health & Human Services and the White House. He holds a Bachelor of Arts from the College of the Holy Cross.

  • Andrew Powell, Esq.

    Director

    Andrew Powell has served as a member of our board of directors since January 2017. He currently serves as a member of the board of Landec Corporation (NASDAQ LNDC), and of various privately held companies in the life sciences industry. Since 2015, Mr. Powell served as senior vice president, general counsel and corporate secretary of Medivation Inc. through the company’s acquisition by Pfizer Inc. in 2016. Prior to Medivation Inc., Mr. Powell served as executive vice president, general counsel and corporate secretary of InterMune Inc. from 2013 to 2015, where he helped the company prepare for the U.S. approval and launch of Esbriet® (pirfenidone) as a treatment for idiopathic pulmonary fibrosis and played a leadership role in InterMune’s acquisition by Swiss drug maker Roche Holdings AG. Early in his career, Mr. Powell held positions of increasing responsibility for nearly 15 years at the multinational health care company Baxter International Inc., where he was instrumental in a series of transactions that established Baxter International throughout Asia. Subsequently, he was part of the senior team that repositioned CollaGenex Pharmaceuticals Inc. as a leader in dermatology. Mr. Powell then served as senior vice president and general counsel at ImClone Systems Inc. where he helped the company grow before playing a key role in a successful process that resulted in a sale to Eli Lilly and Company. Immediately prior to joining InterMune, he was executive vice president, general counsel and secretary at Cornerstone Therapeutics Inc. through its successful sale to Chiesi Farmaceutici S.p.A. Mr. Powell holds a Bachelor of Arts from the University of North Carolina at Chapel Hill and a Juris Doctorate from Stanford Law School.

  • Bryan Reasons

    Director

    Bryan Reasons was appointed to our board of directors in April 2018 and serves as chairman of the audit committee. Mr. Reasons is the chief financial officer of Amneal Pharmaceuticals (NYSE: AMRX). Before joining Amneal, he was vice president, finance of Cephalon Inc. and of Teva Pharmaceutical Industries Ltd., following the acquisition of Cephalon Inc. by Teva. Mr. Reasons previously worked at E.I. Du Pont De Nemours and Company and at Pricewaterhouse Coopers LLP. Since 2017, he has served on the board of directors and the audit committee of Recro Pharma Inc. Mr. Reasons has a Bachelor of Science degree in accounting from the Pennsylvania State University and a Master of Business Administration degree from Widener University. He is a certified public accountant in the Commonwealth of Pennsylvania.

  • Andrew Schiff, M.D.

    Director

    Dr. Schiff has served as a member of Aclaris’ board of directors since August 2017. Dr. Schiff joined Aisling Capital in 1999 and has served as a managing partner since 2006. Prior to joining Aisling Capital, Dr. Schiff practiced internal medicine for six years at the New York Presbyterian Hospital, where he maintains his position as a clinical assistant professor of medicine. Dr. Schiff served as a director of ZELTIQ Aesthetics Inc., a publicly held medical technology company, from 2010 until its acquisition by Allergan in 2017. He also served on the board of directors of Agile Therapeutics Inc., a publicly held women's health specialty pharmaceutical company, from 2012 until 2016. Dr. Schiff currently serves as a director of a number of private companies. He is a longtime supporter and board member of the Visiting Nurse Service of New York, as well as other charitable organizations. Dr. Schiff received his Doctor of Medicine from Cornell University Medical College, his Master of Business Administration from Columbia University, and his Bachelor of Science, with honors in neuroscience, from Brown University.

  • Dr. Neal Walker

    Director, President and CEO

    Dr. Walker co-founded Aclaris and has served as president and CEO and a member of the board of directors since its inception in July 2012. He is a board-certified dermatologist and serial entrepreneur with over 20 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson. Dr. Walker co-founded NeXeption, LLC, a biopharmaceutical assets management company, in 2012. Prior to Aclaris, he co-founded and served as president and CEO and a member of the board of directors of Vicept Therapeutics Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan in 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture); Trigenesis Therapeutics Inc., a specialty dermatology company, where he served as chief medical officer (acquired by Dr. Reddy's Laboratories Ltd.); and Cutix Inc., a commercial dermatology company. He also co-founded and serves on the board of directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is on the board of directors of Aldeyra Therapeutics Inc., a publicly held biotechnology company, as well as Life Sciences Pennsylvania and several private companies. In 2016, Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award and the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology. He received his Master of Business Administration from The Wharton School, University of Pennsylvania, his Doctor of Osteopathic Medicine from the Philadelphia College of Osteopathic Medicine, and a Bachelor of Arts in biology from Lehigh University.